GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Quality Rank

Krystal Biotech (Krystal Biotech) Quality Rank


View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Krystal Biotech Quality Rank Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech (Krystal Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Quality Rank
Comparable Companies
BPMC FOLD NUVL INSM CRSP CYTK IMGN TRML ACAD AXSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
4KB:Germany
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Website
https://www.krystalbio.com
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Executives
Krish S Krishnan director, 10 percent owner, officer: President and CEO 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan director, 10 percent owner, officer: Chief Operating Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Andrew C. Orth officer: Chief Commercial Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano officer: Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi director 61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien officer: Chief Commercial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby director C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v. 10 percent owner POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000